Objective To study the value of allograft inflammatory factor 1(AIF-1), interleukin-6(IL-6) and vascular endothelial growth factor(VEGF) in the diagnosis and prognosis assessment of non-small cell lung cancer(NSCLC). Methods A total of 183 NSCLC patients and 120 healthy subjects were selected.and divided into NSCLC group and control group The expression of serum AIF-1, IL-6 and VEGF were compared between the two groups. The relationship between them and tumor markers such as CEA, SCCA, CYFRA21-1 and clinicopathological features of NSCLC was analyzed. ROC curve was employed to analyze the diagnostic value of the three factors in NSCLC. The relationship between serum AIF-1, IL-6, VEGF and survival was analyzed. Results The serum levels of AIF-1, IL-6 and VEGF in NSCLC patients were higher than those in healthy controls (P<0.05), was positively correlated with CEA, SCCA and CYFRA21-1 (P<0.05). The three factors were related to lymph node metastasis, distant metastasis, tumor differentiation and TNM stage (P<0.05), IL-6 was also associated with cancer tissue size(P<0.05). ROC curve analysis showed that the sensitivity, specificity, area under the curve(AUC) and 95% CI of the three combined detection were 0.88, 0.78, 0.88, 0.84-0.92, respectively, which were better than those of single index. Survival analysis showed that the overall survival rate of NSCLC patients with high expression of AIF-1 and IL-6 was significantly lower than that with low expression of AIF-1 and IL-6 (P<0.05). Conclusion AIF-1, IL-6 and VEGF are involved in the occurrence and development of NSCLC, which are helpful for the clinical diagnosis and prognosis evaluation of NSCLC.

Objective: To analyze the results of enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay (CLIA) in detection of hepatitis B surface antigen (HBsAg) and Treponema pallidum (TP) antibody. Methods: ELISA and CLIA were used to detect HBsAg and TP antibody of 3060 blood samples. HBsAg negative samples were then detected by nucleic acid test (NAT). All the mismatching results of HBsAg and anti-TP detected by ELISA and CLIA were confirmed in National Center for Clinical Laboratories (NCCL). Results: HBsAg tests results: the sensitivity of ELISA and CLIA were all 90.00%, the specificity was 99.87% and 100.00% respectively. 4 cases ELISA positive CLIA negative samples were confirmed negative at last, but 1 positive sample of NAT was confirmed reactive. TP antibody tests results: the sensitivity of ELISA and CLIA was 40.00% and 90.00% respectively, the specificity was 99.84% and 99.97% respectively. 12 ELISA reactive CLIA negative samples were confirmed negative in 11 cases and reactive in 1 case; 8 CLIA positive ELISA negative samples, 6 samples were confirmed reactive while the other 2 were negative. Conclusions: CLIA has high sensitivity and specificity in detecting HBsAg and TP antibody of blood samples.